NLRC5 can restore tumor immunogenicity by increasing MHC I allotypes, creating a potential avenue for therapeutic strategies to restore MHC I antigen presentation as a combinatorial approach with other therapies against primary tumors but also in the context of MHC I downregulation as an intrinsic mechanism for acquired resistance to immunotherapy in cancer patients (69). This evidence concerns the gene NLRC5 and neoplasm.